Revenue Update on Alliqua Biomedical Inc(NASDAQ:ALQA)

Alliqua Biomedical Inc(NASDAQ:ALQA) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Company reported revenue of $4.47M. Analysts estimated a revenue of $5.38M. Earnings per share were $-0.19. Analysts had estimated an EPS of $-0.27.

Alliqua Biomedical Inc (ALQA) shares turned negative on Wednesdays trading session with the shares closing down -0.01 points or -0.90% at a volume of 12,743. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $1.13. The peak price level was also seen at $1.13 while the days lowest was $1.08. Finally the shares closed at $1.1. The 52-week high of the shares is $4.74 while the 52-week low is $0.7. According to the latest information available, the market cap of the company is $33 M.

Several Insider Transactions has been reported to the SEC. On Nov 12, 2015, Jeffrey Sklar (director) purchased 1,500 shares at $2.95 per share price.Also, On Nov 10, 2015, Brian M Posner (CFO) purchased 5,000 shares at $3.04 per share price.On Nov 9, 2015, Bradford Barton (COO) purchased 5,000 shares at $2.97 per share price, according to the Form-4 filing with the securities and exchange commission.

Alliqua BioMedical Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries AquaMed Technologies Inc. and Choice Therapeutics Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of four product categories: Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection the Company offers TheraBond 3D Antimicrobial Barrier Systems (TheraBond) and SilverSeal.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Alliqua Biomedical Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Alliqua Biomedical Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.